29/01/2018 13:30:00

Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Related content
09 May - 
Adamas Announces New Employment Inducement Grant
03 May - 
Adamas Reports First Quarter 2018 Financial Results
02 May - 
Adamas to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the closing of its previously announced underwritten public offering of its common stock. Adamas sold 3,000,000 shares of its common stock, and the underwriters have exercised their option in full to purchase an additional 450,000 shares pursuant to the full exercise of the underwriters’ option, at a price to the public of $41.50 per share. The aggregate gross proceeds from this offering are expected to be $143,175,000, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Adamas. The purchase of the 3,000,000 shares closed on January 26, 2018. The sale of the 450,000 shares is expected to close on January 30, 2018, subject to customary closing conditions. All of the shares of common stock were offered by Adamas.

BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as book-running managers for the offering. A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission on November 3, 2016, and became effective on November 21, 2016. The offering was made only by means of a prospectus supplement. Copies of the prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting BofA Merrill Lynch,  NC1-004-03, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com; Leerink Partners, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525 ext. 6132 or by email at Syndicate@Leerink.com; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Adamas Pharmaceuticals, Inc.

Adamas is a pharmaceutical company committed to developing and commercializing products and product candidates for the treatment of chronic neurological disorders.

For questions, please contact:

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 1st quarter of 2018 and 15 months of 2017/2018
2
ALGT LOSS ALERT: Rosen Law Firm Reminds Allegiant Travel Company Investors of Important Deadline in Class Action– ALGT
3
Cleveland Drug Rehabs, Addiction Isn’t A Disease, It’s Just A Thought in Your Head
4
Quick Weight-Loss Diet Plan To Lose Weight Fast With The 2 Week Diet By Brian Flatt
5
TheRecover.com, Drug Detoxification For San Jose Residents

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 May 2018 04:23:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180515.2 - EUROWEB3 - 2018-05-21 05:23:20 - 2018-05-21 04:23:20 - 1000 - Website: OKAY